PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15686893-1	2005	Considering importance of developing selective estrogen receptor modulators (SERMs), the present paper explores selectivity requirements of tetrahydroisoquinoline derivatives for binding with ER(alpha) versus ER(beta) receptors using E-state index and physicochemical parameters.	1,2,3,4-tetrahydroisoquinoline	140-162	estrogen receptor 1	Homo sapiens	192-200	
18272256-2	2008	Tetrahydroisoquinoline derivatives are a class of selective estrogen receptor modulators (SERMs) with high binding affinity and specificity exhibiting up to 50 folds for ERalpha over ERbeta.	1,2,3,4-tetrahydroisoquinoline	0-22	estrogen receptor 1	Homo sapiens	170-177	
15686893-7	2005	From the analysis it appears that the nitrogen atom of the aminoethoxyphenyl substituent and 6-hydroxy substituent of the tetrahydroisoquinoline nucleus play important roles for ER(alpha)/ER(beta) selectivity in addition to R(1) and R(2) substituents.	1,2,3,4-tetrahydroisoquinoline	122-144	estrogen receptor 1	Homo sapiens	178-187	
12825935-0	2003	Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.	1,2,3,4-tetrahydroisoquinoline	110-132	estrogen receptor 1	Homo sapiens	92-99	
34610548-2	2021	Herein, a series of tetrahydroisoquinoline (THIQ)-hydroxamate conjugates were rationally designed and synthesized as dual SERDs/HDAC inhibitors by incorporating the hydroxamate, a known HDAC pharmacophore, into a privileged THIQ scaffold of selective ERalpha degraders (SERDs).	1,2,3,4-tetrahydroisoquinoline	224-228	estrogen receptor 1	Homo sapiens	251-258	
34610548-2	2021	Herein, a series of tetrahydroisoquinoline (THIQ)-hydroxamate conjugates were rationally designed and synthesized as dual SERDs/HDAC inhibitors by incorporating the hydroxamate, a known HDAC pharmacophore, into a privileged THIQ scaffold of selective ERalpha degraders (SERDs).	1,2,3,4-tetrahydroisoquinoline	20-42	estrogen receptor 1	Homo sapiens	251-258	
34610548-2	2021	Herein, a series of tetrahydroisoquinoline (THIQ)-hydroxamate conjugates were rationally designed and synthesized as dual SERDs/HDAC inhibitors by incorporating the hydroxamate, a known HDAC pharmacophore, into a privileged THIQ scaffold of selective ERalpha degraders (SERDs).	1,2,3,4-tetrahydroisoquinoline	44-48	estrogen receptor 1	Homo sapiens	251-258	
28296398-1	2017	Tetrahydroisoquinoline 40 has been identified as a potent ERalpha antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.	1,2,3,4-tetrahydroisoquinoline	0-22	estrogen receptor 1	Homo sapiens	58-65